Could DEA Registration Denials Put 280E Relief at Risk?

I recently wrote about the DEA issuing federal registrations to more than 900 medical marijuana dispensaries. Although those registrations likely represent far fewer individual companies than the number would suggest, I considered it an encouraging first step toward establishing a federally recognized medical cannabis industry. Unfortunately, we are already seeing problems for businesses in states with combined medical and adult-use licensing, as well as jurisdictions such as Washington, D.C., where patients can self-certify their eligibility without a physician's recommendation.
Now I am hearing warnings from legal professionals that the IRS could use these registration disputes to deny §280E relief, potentially excluding entire state programs that DEA determines do not meet federal requirements. I understand the concern, but I am not convinced that DEA's registration decisions provide a legal basis for that conclusion.
DEA's Proposed Denials
On November 11, Tom Angell reported in DEA Is Rejecting Medical Marijuana Businesses That Want Federal Rescheduling Protections In Multiple States that DEA has issued orders proposing to deny registration applications from medical marijuana businesses in California, Delaware, Washington, D.C., Illinois, North Dakota, and Oregon.
Attorneys at Foley Hoag discussed similar concerns in their article, DEA Guidance Raises Hard Questions for Applicants in Dual Use States. In Minnesota, DEA objected to a dispensary's application because the state's licensing program allows businesses to sell both medical and adult-use cannabis. The agency also raised concerns about patient certification requirements and certain cannabinoid products permitted under state law.
Washington, D.C., presents another problem. The District allows patients 21 and older to self-certify that they use marijuana for medical purposes without a physician's recommendation. On November 6, Chris Roberts reported in Medical Cannabis Dispensary Rejected for DEA Registration as More Federal Marijuana Rescheduling Details Emerge that DEA issued an order to show cause arguing that D.C.'s system violates federal requirements and U.S. treaty obligations regarding prescriptions. DEA stated that it could not register dispensaries operating under D.C.'s program.
These are proposed registration denials, not final decisions. However, they have raised concerns that the IRS could deny §280E relief not only to businesses without federal registration, but also to medical operators in states whose programs DEA considers inconsistent with federal requirements.
I think we need to look more closely at what the rescheduling order actually says.
What the Rescheduling Order Actually Says
Under the April 28, 2026, final order, marijuana subject to a state medical marijuana license was moved to Schedule III, while adult-use marijuana remains in Schedule I. The order defines a state medical marijuana license under 21 CFR §1300.01 as a license issued by a state, D.C., or territorial entity authorizing the manufacture, distribution, or dispensing of marijuana for medical purposes.
Importantly, that definition does not expressly require a state to prohibit adult-use activities under the same license, nor does it require that every aspect of the state's medical program satisfy the separate requirements for federal DEA registration.
DEA is proposing to deny certain registration applications based on federal requirements under 21 CFR §1301.13(k). In Washington, D.C., the agency has objected to the District's self-certification program because patients can obtain marijuana without a practitioner's written certification, which is required under subsection (k)(5).
However, a business failing to qualify for federal registration is not necessarily the same as its state medical marijuana license failing to qualify under the rescheduling order. The regulations establish separate requirements for the classification of marijuana and for obtaining federal authorization to manufacture, distribute, or dispense it.
Registration Is Not the Same Question as Scheduling
Section 280E applies to controlled substances "within the meaning of schedule I and II" of the Controlled Substances Act. It does not expressly require federal registration as a condition for deducting business expenses. Even if a business is prohibited from handling a Schedule III substance because it lacks the required DEA registration, that does not automatically make the substance Schedule I.
I also think the April 23 announcement from Treasury and the IRS provides some reassurance. Treasury acknowledged that rescheduling would generally remove §280E restrictions from qualifying medical activities and specifically anticipated businesses operating in both medical and adult-use markets. The forthcoming guidance is expected to address apportioning expenses between those activities, rather than excluding mixed-use businesses altogether.
I still think the idea of apportioning expenses between medical and adult-use marijuana is preposterous, particularly when the same cannabis can be produced under identical conditions and sold to either type of customer. However, that is a separate issue from whether businesses operating under state medical licenses qualify for §280E relief.
Where This Leaves Operators
There remains a legitimate question about how the IRS might interpret the rescheduling order when a state program permits activities that do not satisfy federal requirements. I cannot rule out the possibility that the IRS could attempt to challenge the Schedule III treatment of certain transactions. But that would require examining whether the marijuana involved was covered by the rescheduling order, not simply whether DEA approved the business's registration application.
For now, neither Treasury nor the IRS has announced that a DEA registration denial disqualifies a business from §280E relief, or that programs such as D.C.'s are categorically excluded. The statutory language, the definition of a state medical marijuana license, and Treasury's announced approach all provide arguments against imposing such a restriction.
I will continue watching these disputes and the forthcoming IRS guidance. I understand why attorneys are warning their clients about the possibility of additional restrictions, particularly given the financial consequences. But I don't believe we should assume that DEA's refusal to register a business gives the IRS authority to deny §280E relief to an entire state medical marijuana program.
Until Treasury or the IRS announces otherwise, a DEA registration dispute should not be treated as a determination that medical marijuana businesses have lost their eligibility for §280E relief.
Related posts
Need expert guidance?
Whether you are navigating 280E, structuring a new venture, or planning for regulatory changes - Calyx CPA can help.
Get in Touch